MMTX — MindMaze Therapeutics Holding SA Share News
0.000.00%
- CH₣34.12m
- CH₣24.65m
- CH₣0.64m
Brief: Relief Therapeutics: NRx Pharmaceuticals Announces Update On Breakthrough Designation For Aviptadil
Brief: Relief Therapeutics Announces Acer Therapeutics Says It Has Not Yet Received A Decision From U.S. FDA For New Drug Application For Acer-001
Swiss stocks - Factors to watch on June 8
Brief: Relief Therapeutics Says It Remains Committed To Continuing Development Of Aviptadil
Relief Therapeutics slumps as U.S. DSMB recommends to cease COVID drug study
Swiss stocks - Factors to watch on March 31
Swiss stocks - Factors to watch on March 21
Brief: Relief Therapeutics Subsidiary Signs Agreement To Commercialize Novel Dosage Form For PKU Treatment
Swiss stocks - Factors to watch on March 15
Swiss stocks - Factors to watch on February 8
Swiss stocks - Factors to watch on January 31
Swiss stocks - Factors to watch on January 27
Brief: NRx Responds To Relief’s Allegations Of January 14, 2022
Swiss stocks - Factors to watch on January 14
Brief: Nrx Pharmaceuticals Files Counterclaim Against Its Former Collaboration Partner, Relief Therapeutics
Swiss stocks - Factors to watch on January 6
Swiss stocks - Factors to watch on January 4
Swiss stocks - Factors to watch on December 16
Swiss stocks - Factors to watch on December 10